Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026)
Viatris (VTRS) posted Net Income towards Common Stockholders of -$118.8 million for Q2 2026, down 167.35% on a QoQ basis from $176.4 million in Q1 2026, and down 2482.61% year-over-year from $5.0 million in Q2 2025.
Analysis
Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Viatris has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$118.8 million in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 2482.61% year-over-year to -$118.8 million in Q2 2026; TTM through Jun 2026 was -$410.7 million, a 88.16% increase from a year earlier, with the FY2025 full-year figure at -$3.5 billion, down 454.23% from the prior year.
- Net Income towards Common Stockholders was -$118.8 million for Q2 2026 at Viatris, down from $176.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $1.0 billion in Q4 2022, with the low at -$3.0 billion in Q1 2025.
- Average Net Income towards Common Stockholders over 5 years is -$108.8 million, with a median of $104.4 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 483.32% in 2022, then sank 2770.76% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at $1.0 billion in 2022, then tumbled by 175.71% to -$765.6 million in 2023, then soared by 32.54% to -$516.5 million in 2024, then surged by 34.15% to -$340.1 million in 2025, then soared by 65.07% to -$118.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$118.8 million (Q2 2026), $176.4 million (Q1 2026), and -$340.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.55 Bn | 38.89 Bn | 2.15 Bn | -576.00 Mn |
| 2 | Viatris | 19.15 Bn | 18.26 Bn | 1.46 Bn | -118.80 Mn |
| 3 | Dr Reddys Laboratories | 9.87 Bn | 9.70 Bn | 396.53 Mn | 46.85 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.32 Bn | 334.51 Mn | 69.61 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 260.00 Mn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | -66.70 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 24.70 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 30.35 Mn |
| 9 | Fennec Pharmaceuticals | 401.76 Mn | 360.51 Mn | 17.15 Mn | 1.97 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -118.80 Mn |
| Mar 31, 2026 | 176.40 Mn |
| Dec 31, 2025 | -340.10 Mn |
| Sep 30, 2025 | -128.20 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.04 Bn |
| Dec 31, 2024 | -516.50 Mn |
| Sep 30, 2024 | 94.80 Mn |
| Jun 30, 2024 | -326.40 Mn |
| Mar 31, 2024 | 113.90 Mn |
| Dec 31, 2023 | -765.60 Mn |
| Sep 30, 2023 | 331.60 Mn |
| Jun 30, 2023 | 264.00 Mn |
| Mar 31, 2023 | 224.70 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 354.30 Mn |
| Jun 30, 2022 | 313.90 Mn |
| Mar 31, 2022 | 399.20 Mn |
| Dec 31, 2021 | -263.80 Mn |
| Sep 30, 2021 | 311.50 Mn |